Management of myeloma bone lesions

Abstract

Multiple myeloma (MM) is a B‐cell neoplasm characterized by clonal plasma–cell prolif-eration. The survival and prognosis of this condition have been significantly improved by treatment with active anti‐MM drugs such as bortezomib or lenalidomide. Further, the discovery of novel agents has recently paved the way for new areas of investigation. However, MM, including mye-loma‐related bone diseases, remains fatal. Bone disease or bone destruction in MM is a consequence of skeletal involvement with bone pain, spinal cord compression, and bone fracture resulting from osteolytic lesions. These consequences affect disease outcomes, including patients’ quality of life and survival. Several studies have sought to better understand MM bone disease (MBD) through the classification of its molecular mechanisms, including osteoclast activation and osteoblast inhi-bition. Bisphosphonates and the receptor activator of the nuclear factor‐kappa B (NF‐κB) ligand (RANKL) inhibitor, denosumab, prevent skeletal‐related events in MM. In addition, several other bone‐targeting agents, including bone‐anabolic drugs, are currently used in preclinical and early clinical evaluations. This review summarizes the current knowledge of the pathogenesis of MBD and discusses novel agents that appear very promising and will soon enter clinical development.